Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25

Benzinga Newsdesk www.benzinga.com Positive 84.5%

Neg 0% Neu 0% Pos 84.5%

Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.